Revised forecast
Fiscal year ending March 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Although stagnation in the European economy is expected to continue for the time being, the company expects to build up orders in the V&S market, see a recovery in sales in overseas healthcare markets, and expand its business in India and the Middle East. The company will increase investment in human capital and research and development, while managing fixed costs through the restructuring of its organization and development and production sites in Europe. Compared with the gain on the sale of investment securities of 7,999 million yen in the previous fiscal year, the company expects a gain of approximately 4,400 million yen in the next fiscal year, and net income attributable to owners of the parent is therefore expected to decrease.
Impairment losses: 497 million yen; loss on disposal of fixed assets: 192 million yen; business restructuring expenses: 441 million yen; loss on revision of retirement benefit plans: 75 million yen; total extraordinary losses: 1,206 million yen (actual results for the fiscal year ended March 2026)
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥85,000 million（4.5% (year-on-year)） |
| Operating profit | Not disclosed → ¥3,300 million（39.5% (year-on-year)） |
| Ordinary income | Not disclosed → ¥4,600 million（21.9% (year-on-year)） |
| Profit attributable to owners of the parent | Not disclosed → ¥6,500 million（△11.2% (year-on-year)） |
| Net income per share | Not disclosed → 167.60 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Previous-period results | Revenue: 81,308 million yen; operating income: 2,365 million yen; ordinary income: 3,772 million yen; net income attributable to owners of the parent: 7,323 million yen; basic earnings per share: 180.64 yen |
| Reason for the revision | Although stagnation in the European economy is expected to continue for the time being, the company expects to build up orders in the V&S market, see a recovery in sales in overseas healthcare markets, and expand its business in India and the Middle East. The company will increase investment in human capital and research and development, while managing fixed costs through the restructuring of its organization and development and production sites in Europe. Compared with the gain on the sale of investment securities of 7,999 million yen in the previous fiscal year, the company expects a gain of approximately 4,400 million yen in the next fiscal year, and net income attributable to owners of the parent is therefore expected to decrease. |
| Details and amount of extraordinary loss | Impairment losses: 497 million yen; loss on disposal of fixed assets: 192 million yen; business restructuring expenses: 441 million yen; loss on revision of retirement benefit plans: 75 million yen; total extraordinary losses: 1,206 million yen (actual results for the fiscal year ended March 2026) |
| Dividend forecast revision | For the fiscal year ending March 2027, annual dividends of 115 yen are planned, comprising an interim dividend of 57.50 yen and a year-end dividend of 57.50 yen. This represents a 5-yen increase from the annual dividend of 110 yen for the current fiscal year. Whether this is a revision from the previous forecast: Not disclosed. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Assuming that the stagnation of the European economy will continue for the time being, the company expects to build up orders in the V&S market, see a recovery in sales in overseas healthcare markets, and expand its business in India and the Middle East. While increasing investment in human capital and research and development, the company will manage fixed costs by restructuring its sales organization in Europe and its development and production sites, as well as improving operational efficiency. Net income attributable to owners of the parent is expected to decrease due to the 7,999 million yen gain on the sale of investment securities recorded in the previous fiscal year.